What is the TITAN study?[1][2]

Broad patient population[1][2]

Key eligibility criteria[2]
  • Castration-sensitive
  • Distant metastatic disease
    (≥1 lesion on bone scan)
  • ECOG PS 0 or 1
  • Prior docetaxel
  • ADT ≤6 months for mHSPC or ≤3 years for local disease
  • Local treatment completed ≥1 year prior
  • Gleason score at diagnosis (≤7 or >7)
  • Region (NA and EU vs. all other countries)
  • Prior docetaxel (yes vs. no)
  • Newly diagnosed M1 or M1 following prior treatment
On-study requirement[2]
  • Continuous ADT

Study design[1][2]

N=1052 (December 2015–July 2017)[1][2]
TITAN study design

Adapted from Chi KN, et al. 2021 & Chi KN, et al. 2019.

Dual primary endpoints[1]
  • rPFS
  • OS

Secondary endpoints[1]
  1. Time to initiation of cytotoxic chemotherapy
  2. Time to pain progression
  3. Time to chronic opioid use
  4. Time to skeletal-related event

Other clinically relevant endpoints[1]
  • Time to symptomatic local progression
  • Time to PSA progressiona
  • PFS2

aBased on Prostate Cancer Clinical Trials Working Group 2 criteria.[1]

Click below to find out more about the clinical benefits with ERLEADA® + ADT:

Increase survival and delay progression

Treat early with ERLEADA® + ADT to delay progression and extend life for your mHSPC patients vs. placebo + ADT[1]

ERLEADA® provides an additional treatment option

Give patients with mHSPC the opportunity for an additional treatment option upon disease progression[1][2]

Maintain QoL

Push back on progression and maintain QoL in mHSPC[1]


ADT, androgen deprivation therapy. ECOG, Eastern Cooperative Oncology Group. EU, European Union. M1, metastasised outside the pelvis. mHSPC, metastatic hormone-sensitive prostate cancer. NA, North America. OS, overall survival. PFS2, second progression-free survival. PS, performance status. PSA, prostate-specific antigen. QD, once-daily. rPFS, radiographic progression-free survival. Rx, prescription.

CP-425776 - November 2023